{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:55:58Z","timestamp":1787684158527,"version":"build-2784847793"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11302-026-10172-4","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:04:38Z","timestamp":1781845478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selective P2X3 versus dual P2X2\/3 receptor antagonists in refractory chronic cough: a systematic review and dose\u2013response meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"22","author":[{"given":"Jeevarathinam","family":"Thirumalai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saravanan","family":"Sekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"10172_CR1","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(14)61255-1","volume":"385","author":"R Abdulqawi","year":"2015","unstructured":"Abdulqawi R, Dockry R, Holt K et al (2015) P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385:1198\u20131205. https:\/\/doi.org\/10.1016\/S0140-6736(14)61255-1","journal-title":"Lancet"},{"key":"10172_CR2","doi-asserted-by":"publisher","first-page":"1901615","DOI":"10.1183\/13993003.01615-2019","volume":"55","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Butera P et al (2020) Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J 55:1901615. https:\/\/doi.org\/10.1183\/13993003.01615-2019","journal-title":"Eur Respir J"},{"key":"10172_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/S2213-2600(19)30471-0","volume":"8","author":"JA Smith","year":"2020","unstructured":"Smith JA, Kitt MM, Morice AH et al (2020) Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial. Lancet Respir Med 8:775\u2013785","journal-title":"Lancet Respir Med"},{"key":"10172_CR4","doi-asserted-by":"crossref","unstructured":"Morice AH, Kitt MM, Ford AP, et al (2019) The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study. European Respiratory J 54","DOI":"10.1183\/13993003.00439-2019"},{"key":"10172_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(21)02348-5","volume":"399","author":"LP McGarvey","year":"2022","unstructured":"McGarvey LP, Birring SS, Morice AH et al (2022) Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. The Lancet 399:909\u2013923","journal-title":"The Lancet"},{"key":"10172_CR6","doi-asserted-by":"publisher","first-page":"e4112","DOI":"10.1002\/cbf.4112","volume":"42","author":"D Ezhilarasan","year":"2024","unstructured":"Ezhilarasan D, Langeswaran K (2024) Hepatocellular interactions of potential nutraceuticals in the management of inflammatory NAFLD. Cell Biochem Funct 42:e4112","journal-title":"Cell Biochem Funct"},{"key":"10172_CR7","doi-asserted-by":"publisher","first-page":"1901136","DOI":"10.1183\/13993003.01136-2019","volume":"55","author":"AH Morice","year":"2020","unstructured":"Morice AH, Millqvist E, Bieksiene K et al (2020) ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. Eur Respir J 55:1901136","journal-title":"Eur Respir J"},{"key":"10172_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1164\/rccm.202409-1752OC","volume":"211","author":"JA Smith","year":"2025","unstructured":"Smith JA, Birring SS, Blaiss MS et al (2025) Camlipixant in refractory chronic cough: a phase 2b, randomized, placebo-controlled trial (SOOTHE). Am J Respir Crit Care Med 211:1038\u20131048","journal-title":"Am J Respir Crit Care Med"},{"key":"10172_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","volume":"201","author":"L McGarvey","year":"2023","unstructured":"McGarvey L, Smith JA, Morice A et al (2023) A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough. Lung 201:25\u201335","journal-title":"Lung"},{"key":"10172_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04240-2020","author":"A Morice","year":"2021","unstructured":"Morice A, Smith JA, McGarvey L et al (2021) Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.04240-2020","journal-title":"Eur Respir J"},{"key":"10172_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/CIRCRESAHA.116.309726","volume":"120","author":"G Burnstock","year":"2017","unstructured":"Burnstock G (2017) Purinergic signaling in the cardiovascular system. Circ Res 120:207\u2013228","journal-title":"Circ Res"},{"key":"10172_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1113\/expphysiol.2013.071951","volume":"99","author":"G Burnstock","year":"2014","unstructured":"Burnstock G (2014) Purinergic signalling: from discovery to current developments. Exp Physiol 99:16\u201334","journal-title":"Exp Physiol"},{"key":"10172_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1748-1716.2009.01957.x","volume":"195","author":"G Burnstock","year":"2009","unstructured":"Burnstock G, Verkhratsky A (2009) Evolutionary origins of the purinergic signalling system. Acta Physiol (Oxf) 195:415\u2013447","journal-title":"Acta Physiol (Oxf)"},{"key":"10172_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"key":"10172_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fncel.2013.00267","volume":"7","author":"AP Ford","year":"2013","unstructured":"Ford AP, Undem BJ (2013) The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci 7:267","journal-title":"Front Cell Neurosci"},{"key":"10172_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/35039519","volume":"407","author":"DA Cockayne","year":"2000","unstructured":"Cockayne DA, Hamilton SG, Zhu Q-M et al (2000) Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature 407:1011\u20131015","journal-title":"Nature"},{"key":"10172_CR17","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1152\/physrev.00015.2002","volume":"82","author":"RA North","year":"2002","unstructured":"North RA (2002) Molecular physiology of P2X receptors. Physiol Rev 82:1013\u20131067","journal-title":"Physiol Rev"},{"key":"10172_CR18","doi-asserted-by":"crossref","unstructured":"Zheng Z, Huang J, Xiang Z, et al (2023) Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis. EClinicalMedicine 62","DOI":"10.1016\/j.eclinm.2023.102100"},{"key":"10172_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S2213-2600(21)00125-9","volume":"9","author":"W-J Song","year":"2021","unstructured":"Song W-J, Hui CK, Hull JH et al (2021) Confronting COVID-19-associated cough and the post-COVID syndrome: role of viral neurotropism, neuroinflammation, and neuroimmune responses. Lancet Respir Med 9:533\u2013544","journal-title":"Lancet Respir Med"},{"key":"10172_CR20","doi-asserted-by":"crossref","unstructured":"Fraj E, Merzouki M, Bourhou C, et al (2026) Unveiling the Therapeutic Potential of Flavones: A Review on Biological Activities and Mechanisms. Phytotherapy Research","DOI":"10.1002\/ptr.70236"},{"key":"10172_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pupt.2015.10.007","volume":"35","author":"M Hennel","year":"2015","unstructured":"Hennel M, Brozmanova M, Kollarik M (2015) Cough reflex sensitization from esophagus and nose. Pulm Pharmacol Ther 35:117\u2013121","journal-title":"Pulm Pharmacol Ther"},{"key":"10172_CR22","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj 372","DOI":"10.1136\/bmj.n71"},{"key":"10172_CR23","unstructured":"Jpt H (2008) Cochrane handbook for systematic reviews of interventions. http:\/\/www.cochrane-handbook.org"},{"key":"10172_CR24","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/sim.1009","volume":"20","author":"J Hartung","year":"2001","unstructured":"Hartung J, Knapp G (2001) A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med 20:3875\u20133889","journal-title":"Stat Med"},{"key":"10172_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JA Sterne","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"10172_CR26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"10172_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s41030-022-00193-w","volume":"8","author":"JA Smith","year":"2022","unstructured":"Smith JA, Kitt MM, Bell A et al (2022) Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial. Pulm Ther 8:297\u2013310. https:\/\/doi.org\/10.1007\/s41030-022-00193-w","journal-title":"Pulm Ther"},{"key":"10172_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pupt.2019.03.006","volume":"56","author":"D Muccino","year":"2019","unstructured":"Muccino D, Green S (2019) Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough. Pulm Pharmacol Ther 56:75\u201378. https:\/\/doi.org\/10.1016\/j.pupt.2019.03.006","journal-title":"Pulm Pharmacol Ther"},{"key":"10172_CR29","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s00018-007-6497-0","volume":"64","author":"G Burnstock","year":"2007","unstructured":"Burnstock G (2007) Purine and pyrimidine receptors. Cell Mol Life Sci 64:1471\u20131483. https:\/\/doi.org\/10.1007\/s00018-007-6497-0","journal-title":"Cell Mol Life Sci"},{"key":"10172_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11302-011-9271-6","volume":"8","author":"AP Ford","year":"2012","unstructured":"Ford AP (2012) In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signalling 8:3\u201326. https:\/\/doi.org\/10.1007\/s11302-011-9271-6","journal-title":"Purinergic Signalling"},{"key":"10172_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.coph.2009.02.004","volume":"9","author":"ER Lazarowski","year":"2009","unstructured":"Lazarowski ER, Boucher RC (2009) Purinergic receptors in airway epithelia. Curr Opin Pharmacol 9:262\u2013267. https:\/\/doi.org\/10.1016\/j.coph.2009.02.004","journal-title":"Curr Opin Pharmacol"},{"key":"10172_CR32","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1007\/s10787-025-01926-4","volume":"33","author":"SN Pandey","year":"2025","unstructured":"Pandey SN, Babu MA, Goyal K et al (2025) Targeting NLRP3 inflammasome with curcumin: mechanisms and therapeutic promise in chronic inflammation. Inflammopharmacology 33:5667\u20135687","journal-title":"Inflammopharmacology"},{"key":"10172_CR33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1378\/chest.14-1481","volume":"146","author":"BJ Canning","year":"2014","unstructured":"Canning BJ, Chang AB, Bolser DC et al (2014) Anatomy and Neurophysiology of Cough. Chest 146:1633\u20131648. https:\/\/doi.org\/10.1378\/chest.14-1481","journal-title":"Chest"},{"key":"10172_CR34","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1152\/physrev.00039.2015","volume":"96","author":"SB Mazzone","year":"2016","unstructured":"Mazzone SB, Undem BJ (2016) Vagal Afferent Innervation of the Airways in Health and Disease. Physiol Rev 96:975\u20131024. https:\/\/doi.org\/10.1152\/physrev.00039.2015","journal-title":"Physiol Rev"},{"key":"10172_CR35","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S2213-2600(13)70043-2","volume":"1","author":"KF Chung","year":"2013","unstructured":"Chung KF, McGarvey L, Mazzone SB (2013) Chronic cough as a neuropathic disorder. Lancet Respir Med 1:414\u2013422. https:\/\/doi.org\/10.1016\/S2213-2600(13)70043-2","journal-title":"Lancet Respir Med"},{"key":"10172_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1183\/09031936.98.11010014","volume":"11","author":"JH Ficker","year":"1998","unstructured":"Ficker JH, Dertinger SH, Siegfried W et al (1998) Obstructive sleep apnoea and diabetes mellitus: the role of cardiovascular autonomic neuropathy. Eur Respir J 11:14\u201319. https:\/\/doi.org\/10.1183\/09031936.98.11010014","journal-title":"Eur Respir J"},{"key":"10172_CR37","doi-asserted-by":"publisher","unstructured":"Kinnamon SC, Finger TE (2013) A taste for ATP: neurotransmission in taste buds. Front Cell Neurosci 7. https:\/\/doi.org\/10.3389\/fncel.2013.00264","DOI":"10.3389\/fncel.2013.00264"},{"key":"10172_CR38","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.tips.2004.09.009","volume":"25","author":"SM Reynolds","year":"2004","unstructured":"Reynolds SM, Mackenzie AJ, Spina D, Page CP (2004) The pharmacology of cough. Trends Pharmacol Sci 25:569\u2013576. https:\/\/doi.org\/10.1016\/j.tips.2004.09.009","journal-title":"Trends Pharmacol Sci"},{"key":"10172_CR39","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/thx.2006.067413","volume":"62","author":"S Clare Decalmer","year":"2007","unstructured":"Clare Decalmer S, Webster D, Alice Kelsall A et al (2007) Chronic cough: how do cough reflex sensitivity and subjective assessments correlate with objective cough counts during ambulatory monitoring? Thorax 62:329\u2013334. https:\/\/doi.org\/10.1136\/thx.2006.067413","journal-title":"Thorax"},{"key":"10172_CR40","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0140-6736(08)60596-6","volume":"371","author":"ID Pavord","year":"2008","unstructured":"Pavord ID, Chung KF (2008) Management of chronic cough. Lancet 371:1375\u20131384. https:\/\/doi.org\/10.1016\/S0140-6736(08)60596-6","journal-title":"Lancet"},{"key":"10172_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/00325481.2021.1914944","volume":"133","author":"P Kardos","year":"2021","unstructured":"Kardos P, Blaiss M, Dicpinigaitis P (2021) Addressing unmet needs for diagnosis and management of chronic cough in the primary care setting. Postgrad Med 133:481\u2013488. https:\/\/doi.org\/10.1080\/00325481.2021.1914944","journal-title":"Postgrad Med"},{"key":"10172_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h5590","author":"PG Gibson","year":"2015","unstructured":"Gibson PG, Vertigan AE (2015) Management of chronic refractory cough. BMJ. https:\/\/doi.org\/10.1136\/bmj.h5590","journal-title":"BMJ"},{"key":"10172_CR43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.pupt.2017.04.001","volume":"47","author":"SS Birring","year":"2017","unstructured":"Birring SS, Floyd S, Reilly CC, Cho PSP (2017) Physiotherapy and Speech and Language therapy intervention for chronic cough. Pulm Pharmacol Ther 47:84\u201387. https:\/\/doi.org\/10.1016\/j.pupt.2017.04.001","journal-title":"Pulm Pharmacol Ther"},{"key":"10172_CR44","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1183\/09031936.00057407","volume":"31","author":"SS Birring","year":"2008","unstructured":"Birring SS, Fleming T, Matos S et al (2008) The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J 31:1013\u20131018. https:\/\/doi.org\/10.1183\/09031936.00057407","journal-title":"Eur Respir J"},{"key":"10172_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00408-009-9185-z","volume":"188","author":"AH Morice","year":"2010","unstructured":"Morice AH (2010) The Cough Hypersensitivity Syndrome: A Novel Paradigm for Understanding Cough. Lung 188:87\u201390. https:\/\/doi.org\/10.1007\/s00408-009-9185-z","journal-title":"Lung"},{"key":"10172_CR46","unstructured":"Team RC (2020) RA language and environment for statistical computing, R Foundation for Statistical. Computing"},{"key":"10172_CR47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Mental Health 22:153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Mental Health"},{"key":"10172_CR48","doi-asserted-by":"publisher","unstructured":"Viechtbauer W (2010) Conducting Meta-Analyses in R with the metafor Package. J Stat Soft 36:. https:\/\/doi.org\/10.18637\/jss.v036.i03","DOI":"10.18637\/jss.v036.i03"},{"key":"10172_CR49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/aje\/kwr265","volume":"175","author":"N Orsini","year":"2012","unstructured":"Orsini N, Li R, Wolk A et al (2012) Meta-Analysis for Linear and Nonlinear Dose-Response Relations: Examples, an Evaluation of Approximations, and Software. Am J Epidemiol 175:66\u201373. https:\/\/doi.org\/10.1093\/aje\/kwr265","journal-title":"Am J Epidemiol"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10172-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10172-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10172-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:12:24Z","timestamp":1787577144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-026-10172-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10172"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10172-4","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This systematic review and meta-analysis was conducted using data from published trial reports and clinical trial registries. No primary data collection involving human participants was performed; therefore, ethical approval and patient consent were not required for this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"59"}}